People aged 12+ who have Down’s syndrome are among thousands of the UK’s most vulnerable people who will be the first in the world to be offered life-saving, cutting-edge antiviral and antibody treatments that they can take from home. It is hoped the treatments can help protect those most at risk from the virus over the winter months.
Read the latest from the NHS about the new treatments here
Those at highest risk who test positive for the virus via a PCR test – for example, people who are immunocompromised, cancer patients or people who have Down’s syndrome – will also be able to access either Molnupiravir or the novel monoclonal antibody Ronaprebe from 16 December.
Molnupiravir has shown in clinical trials to reduce the risk of hospitalisation or death for at-risk, non-hospitalised adults with mild to moderate Covid-19 by 30% and Ronapreve reduced the risk by 70%.
Health and Social Care Secretary Sajid Javid said:
“The UK is a world-leader in rolling out innovative treatments to the patients who need them and today is a historic milestone in our battle against the virus, deploying the first medicines vulnerable people will be able to take outside of hospital and in the comfort of their own homes to protect themselves.
This opens up a new era for the treatment of Covid-19, one where we can begin to cover every phase of contracting this deadly disease – whether it be before you catch it, just after you catch it, if you develop symptoms or if you require hospital care.
Those in the highest risk group (which includes people who have Down’s syndrome aged 12+), will be informed by the NHS if they have a condition that will make them eligible to receive these treatments, should they test positive via a PCR for Covid-19.
The eligible cohorts have been determined by an independent expert group commissioned by the Department of Health and Social Care (DHSC) and included in a clinical policy agreed by all four Chief Medical Officers in the UK.
These patients will be able to keep a PCR test at home from NHS Test and Trace to support rapid testing, so they can access the treatments as soon as possible after symptoms begin.
Eligible patients who receive a positive test will be assessed over the phone by an expert clinician from an NHS COVID Medicines Delivery Unit (CMDU), who will review and discuss with the patient what the most appropriate treatment would be for them.
Those being prescribed a Monoclonal antibody treatment will be invited to attend the CMDU, while those receiving Molnupiravir can either get someone to collect it for them or have it delivered to their home. The NHS has been setting up CMDUs since the summer.
Antivirals are treatments used to either treat those who are infected with a virus or protect exposed individuals from becoming infected. They target the virus at an early stage, preventing progression to more severe, or even critical, symptoms.
Read more about the treatments here
